Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy
In conclusion, the study demonstrated an application of mechanism driven approach at early stage of a rare disease drug development to support lead compound optimization, e nable human dose, pharmacokinetics, and efficacy predictions.
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Hoa Q. Nguyen,
Andrea Iskenderian,
David Ehmann,
Paul Jasper,
Zhiwei Zhang,
Haojing Rong,
Devin Welty,
Rangaraj Narayanan Tags: ARTICLE Source Type: research
More News: Drugs & Pharmacology | Muscular Dystrophy | Rare Diseases | Reflex Sympathetic Dystrophy | Study